51. A dioxidovanadium (V) complex of NNO-donor Schiff base as a selective inhibitor of protein tyrosine phosphatase 1B: Synthesis, characterization, and biological activities
- Author
-
Liping Lu, Xueqi Fu, Yuqi Jia, Miaoli Zhu, Caixia Yuan, and Shu Xing
- Subjects
Models, Molecular ,Stereochemistry ,Electrospray ionization ,Antineoplastic Agents ,010402 general chemistry ,Crystallography, X-Ray ,01 natural sciences ,chemistry.chemical_compound ,Drug Discovery ,Organometallic Compounds ,Humans ,Cytotoxicity ,IC50 ,Schiff Bases ,Cell Proliferation ,Pharmacology ,Protein Tyrosine Phosphatase, Non-Receptor Type 1 ,Schiff base ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Cell growth ,Organic Chemistry ,General Medicine ,Hep G2 Cells ,0104 chemical sciences ,Blot ,Phosphorylation ,Vanadates ,Selectivity ,hormones, hormone substitutes, and hormone antagonists - Abstract
A new dioxidovanadium (V) complex, VO2(HPPCH) (1) (H2PPCH = N'-picolinoylpyridin-1-ium-2-carbohydrazonate) has been synthesized and characterized by elemental analysis, IR, X-ray diffraction analysis and electrospray ionization mass spectra. Complex 1 crystallized in the monoclinic system with space group P21/c. It potently inhibited PTP1B with IC50 of 0.13 μM, about 7, 15 and 125-fold stronger against PTP1B than over TCPTP, SHP-1 and SHP-2, displaying obvious selectivity against PTP1B. Western blotting analysis indicated that complex 1 effectively increased the phosphorylation of PTP1B substrates, especially the phosphorylation of IR/IGF 1R and IRS-1. It exhibited lower cytotoxicity than positive control VOSO4. These results make complex 1 a promising candidate for novel anti-diabetic drug development.
- Published
- 2016